{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:39:00Z","timestamp":1794749940604,"version":"4.9.1"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01775-x","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T23:00:15Z","timestamp":1748991615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials"],"prefix":"10.1186","volume":"17","author":[{"given":"Glenn A.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren R.","family":"Hirschfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn C.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"1","key":"1775_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13024-022-00533-z","volume":"17","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Wu KM, Yang L, Dong Q, Yu JT. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17(1):28.","journal-title":"Mol Neurodegener"},{"key":"1775_CR2","doi-asserted-by":"crossref","unstructured":"Samudra N, Lane-Donovan C, VandeVrede L, Boxer AL. Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. J Clin Invest. 2023;133(12).","DOI":"10.1172\/JCI168553"},{"issue":"1","key":"1775_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-051222-120750","volume":"19","author":"BC Creekmore","year":"2024","unstructured":"Creekmore BC, Watanabe R, Lee EB. Neurodegenerative disease tauopathies. Annu Rev Pathol. 2024;19(1):345\u201370.","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"1775_CR4","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1007\/s00415-024-12314-3","volume":"271","author":"F Langerscheidt","year":"2024","unstructured":"Langerscheidt F, Wied T, Al Kabbani MA, van Eimeren T, Wunderlich G, Zempel H. Genetic forms of tauopathies: inherited causes and implications of alzheimer\u2019s disease-like TAU pathology in primary and secondary tauopathies. J Neurol. 2024;271(6):2992\u20133018.","journal-title":"J Neurol"},{"key":"1775_CR5","doi-asserted-by":"crossref","unstructured":"Olfati N, Shoeibi A, Litvan I. Clinical spectrum of tauopathies. Front Neurol. 2022;13.","DOI":"10.3389\/fneur.2022.944806"},{"issue":"2","key":"1775_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer\u2019s disease: epidemiology and clinical progression. Neurol Ther. 2022;11(2):553\u201369.","journal-title":"Neurol Ther"},{"key":"1775_CR7","doi-asserted-by":"crossref","unstructured":"Neumann M, Lee EB, Mackenzie IR. In. Frontotemporal Lobar degeneration TDP-43-Immunoreactive pathological subtypes: clinical and mechanistic significance. 2021. pp. 201\u201317.","DOI":"10.1007\/978-3-030-51140-1_13"},{"issue":"1","key":"1775_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):22\u201335.","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"1775_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41580-024-00753-9","volume":"25","author":"C Parra Bravo","year":"2024","unstructured":"Parra Bravo C, Naguib SA, Gan L. Cellular and pathological functions of Tau. Nat Rev Mol Cell Biol. 2024;25(11):845\u201364.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"1775_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T, Noble W, Hanger DP. Roles of Tau protein in health and disease. Acta Neuropathol. 2017;133(5):665\u2013704.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"1775_CR11","doi-asserted-by":"publisher","first-page":"a006247","DOI":"10.1101\/cshperspect.a006247","volume":"2","author":"EM Mandelkow","year":"2012","unstructured":"Mandelkow EM, Mandelkow E. Biochemistry and cell biology of Tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2(7):a006247.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"1775_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-021-00476-x","volume":"16","author":"Deun Chung","year":"2021","unstructured":"Chung Deun, Roemer C, Petrucelli S, Dickson L. Cellular and pathological heterogeneity of primary tauopathies. Mol Neurodegener. 2021;16(1):57.","journal-title":"Mol Neurodegener"},{"issue":"23","key":"1775_CR13","doi-asserted-by":"publisher","first-page":"8948","DOI":"10.3390\/ijms21238948","volume":"21","author":"MC Silva","year":"2020","unstructured":"Silva MC, Haggarty SJ. Tauopathies: Deciphering disease mechanisms to develop effective therapies. Int J Mol Sci. 2020;21(23):8948.","journal-title":"Int J Mol Sci"},{"key":"1775_CR14","doi-asserted-by":"crossref","unstructured":"Chang CW, Shao E, Mucke L, Tau. Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies. Science. 2021;371(6532).","DOI":"10.1126\/science.abb8255"},{"key":"1775_CR15","doi-asserted-by":"crossref","unstructured":"Cornblath EJ, Li HL, Changolkar L, Zhang B, Brown HJ, Gathagan RJ et al. Computational modeling of Tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor. Sci Adv. 2021;7(24).","DOI":"10.1126\/sciadv.abg6677"},{"issue":"1","key":"1775_CR16","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/s41467-020-15701-2","volume":"11","author":"JW Vogel","year":"2020","unstructured":"Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC, et al. Spread of pathological Tau proteins through communicating neurons in human alzheimer\u2019s disease. Nat Commun. 2020;11(1):2612.","journal-title":"Nat Commun"},{"issue":"10","key":"1775_CR17","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.tins.2023.07.006","volume":"46","author":"B Frost","year":"2023","unstructured":"Frost B. Alzheimer\u2019s disease and related tauopathies: disorders of disrupted neuronal identity. Trends Neurosci. 2023;46(10):797\u2013813.","journal-title":"Trends Neurosci"},{"issue":"6","key":"1775_CR18","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","volume":"183","author":"H Wesseling","year":"2020","unstructured":"Wesseling H, Mair W, Kumar M, Schlaffner CN, Tang S, Beerepoot P, et al. Tau PTM profiles identify patient heterogeneity and stages of alzheimer\u2019s disease. Cell. 2020;183(6):1699\u2013e171313.","journal-title":"Cell"},{"key":"1775_CR19","doi-asserted-by":"crossref","unstructured":"Sandhof CA, Murray HFB, Silva MC, Haggarty SJ. Targeted protein degradation with bifunctional molecules as a novel therapeutic modality for alzheimer\u2019s disease & beyond. Neurotherapeutics. 2024;e00499.","DOI":"10.1016\/j.neurot.2024.e00499"},{"key":"1775_CR20","doi-asserted-by":"publisher","unstructured":"Forrest SL, Kovacs GG. Current concepts and molecular pathology of neurodegenerative diseases. Pathology [Internet]. 2024 Dec 12 [cited 2025 Jan 17];57(2):178\u201390. Available from: https:\/\/doi.org\/10.1016\/j.pathol.2024.10.006","DOI":"10.1016\/j.pathol.2024.10.006"},{"issue":"11","key":"1775_CR21","doi-asserted-by":"publisher","first-page":"8129","DOI":"10.1002\/alz.14250","volume":"20","author":"HH Feldman","year":"2024","unstructured":"Feldman HH, Cummings JL, Boxer AL, Staffaroni AM, Knopman DS, Sukoff Rizzo SJ, et al. A framework for translating tauopathy therapeutics: drug discovery to clinical trials. Alzheimer\u2019s Dement. 2024;20(11):8129\u201352.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1775_CR22","doi-asserted-by":"crossref","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2024;10(2).","DOI":"10.1002\/trc2.12465"},{"issue":"1","key":"1775_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9(1):211.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1775_CR24","doi-asserted-by":"publisher","first-page":"e00321","DOI":"10.1016\/j.neurot.2024.e00321","volume":"21","author":"C Lane-Donovan","year":"2024","unstructured":"Lane-Donovan C, Boxer AL. Disentangling tau: one protein, many therapeutic approaches. Neurotherapeutics. 2024;21(2):e00321.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1775_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13195-023-01321-7","volume":"15","author":"JL Cummings","year":"2023","unstructured":"Cummings JL, Gonzalez MI, Pritchard MC, May PC, Toledo-Sherman LM, Harris GA. The therapeutic landscape of tauopathies: challenges and prospects. Alzheimers Res Ther. 2023;15(1):168.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1775_CR26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/brain\/awq367","volume":"134","author":"K Ruscher","year":"2011","unstructured":"Ruscher K, Shamloo M, Rickhag M, Ladunga I, Soriano L, Gisselsson L, et al. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain. 2011;134(3):732\u201346.","journal-title":"Brain"},{"issue":"9","key":"1775_CR27","doi-asserted-by":"publisher","first-page":"7767","DOI":"10.3390\/ijms24097767","volume":"24","author":"S Couly","year":"2023","unstructured":"Couly S, Yasui Y, Su TP. SIGMAR1 confers innate resilience against neurodegeneration. Int J Mol Sci. 2023;24(9):7767.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1775_CR28","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.tjpad.2024.100016","volume":"12","author":"S Macfarlane","year":"2025","unstructured":"Macfarlane S, Grimmer T, Teo K, O\u2019Brien TJ, Woodward M, Grunfeld J, et al. Blarcamesine for the treatment of early alzheimer\u2019s disease: results from the ANAVEX2-73-AD-004 phase IIB\/III trial. J Prev Alzheimers Dis. 2025;12(1):100016.","journal-title":"J Prev Alzheimers Dis"},{"key":"1775_CR29","unstructured":"New Phase IIb\/III Clinical Data Demonstrates Over Three Years of Continuous Treatment. with Oral Blarcamesine to Significantly Benefit Early Alzheimer\u2019s Disease Patients [Internet]. New York; 2025 Jan [cited 2025 Feb 9]. Available from: https:\/\/www.biospace.com\/press-releases\/new-phase-iib-iii-clinical-data-demonstrates-over-three-years-of-continuous-treatment-with-oral-blarcamesine-to-significantly-benefit-early-alzheimers-disease-patients"},{"key":"1775_CR30","unstructured":"Anavex Life Sciences Corporation. Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer\u2019s Disease [Internet]. 2024 Dec [cited 2024 Dec 31]. Available from: https:\/\/www.anavex.com\/post\/blarcamesine-receives-ema-filing-acceptance-for-treatment-of-alzheimer-s-disease"},{"key":"1775_CR31","volume-title":"AD\/PD 2024","author":"Claude Wischik","year":"2024","unstructured":"Claude Wischik. 24-month topline results from phase III LUCIDITY trial in AD show combined disease-modifying and symptomatic activity for HMTM. AD\/PD 2024. Lisbon: KENES; 2024."},{"issue":"4","key":"1775_CR32","doi-asserted-by":"publisher","first-page":"780","DOI":"10.14283\/jpad.2022.63","volume":"9","author":"CM Wischik","year":"2022","unstructured":"Wischik CM, Bentham P, Gauthier S, Miller S, Kook K, Schelter BO. Oral Tau aggregation inhibitor for alzheimer\u2019s disease: design, progress and basis for selection of the 16\u00a0mg\/day dose in a phase 3, randomized, Placebo-Controlled trial of hydromethylthionine mesylate. J Prev Alzheimers Dis. 2022;9(4):780\u201390.","journal-title":"J Prev Alzheimers Dis"},{"key":"1775_CR33","unstructured":"TauRX Therapeutics Ltd. MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM [Internet]. 2024 Jul [cited 2024 Dec 31]. Available from: https:\/\/taurx.com\/news\/industry-news\/mhra-confirms-acceptance-of-uk-marketing-authorisation-application-for-hmtm"},{"issue":"2","key":"1775_CR34","doi-asserted-by":"publisher","first-page":"e32147","DOI":"10.1371\/journal.pone.0032147","volume":"7","author":"CL Reading","year":"2012","unstructured":"Reading CL, Frincke JM, White SK. Molecular targets for 17\u03b1-Ethynyl-5-Androstene-3\u03b2,7\u03b2,17\u03b2-Triol, an Anti-Inflammatory agent derived from the human metabolome. PLoS ONE. 2012;7(2):e32147.","journal-title":"PLoS ONE"},{"key":"1775_CR35","first-page":"969418","volume":"2012","author":"F Nicoletti","year":"2012","unstructured":"Nicoletti F, Philippens I, Fagone P, Ahlem CN, Reading CL, Frincke JM, et al. 17\u03b1-Ethynyl-androst-5-ene-3\u03b2,7\u03b2,17\u03b2-triol (HE3286) is neuroprotective and reduces motor impairment and neuroinflammation in a murine MPTP model of parkinson\u2019s disease. Parkinsons Dis. 2012;2012:969418.","journal-title":"Parkinsons Dis"},{"issue":"30","key":"1775_CR36","doi-asserted-by":"publisher","first-page":"e39027","DOI":"10.1097\/MD.0000000000039027","volume":"103","author":"J Haroon","year":"2024","unstructured":"Haroon J, Jordan K, Mahdavi K, Rindner E, Becerra S, Surya JR, et al. A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias. Medicine. 2024;103(30):e39027.","journal-title":"Medicine"},{"key":"1775_CR37","unstructured":"BioVie Inc. BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer\u2019s Disease [Internet]. 2023 Nov [cited 2024 Dec 31]. Available from: https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=5901034322848314"},{"key":"1775_CR38","unstructured":"BioVie Announces Pipeline Update and Near-. Term Clinical Priorities [Internet]. Carson City; 2024 Mar [cited 2025 Feb 10]. Available from: https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=6444783865331873"},{"issue":"1","key":"1775_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13195-024-01490-z","volume":"16","author":"D Galasko","year":"2024","unstructured":"Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, et al. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of posiphen in subjects with early alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):151.","journal-title":"Alzheimers Res Ther"},{"key":"1775_CR40","unstructured":"Annovis Bio Inc. Improvements in Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap [Internet]. 2024 Jul [cited 2024 Dec 31]. Available from: https:\/\/www.annovisbio.com\/press-release\/annovis-bio-announces-new-data-from-phase-iii-parkinsons-study-highlighting-improvements-in-unified-parkinsons-disease-rating-scale-mds-updrs-and-cognition-after-treatment-with-buntanetap"},{"key":"1775_CR41","unstructured":"Annovis Bio Inc. FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer\u2019s Disease Study, Streamlining Development Pathway [Internet]. 2025 Jan [cited 2025 Feb 2]. Available from: https:\/\/www.annovisbio.com\/press-release\/fda-accepts-final-protocol-for-pivotal-phase-3-alzheimers-disease-study-streamlining-development-pathway"},{"issue":"1","key":"1775_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","volume":"8","author":"M Roberts","year":"2020","unstructured":"Roberts M, Sevastou I, Imaizumi Y, Mistry K, Talma S, Dey M, et al. Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of Tau for passive immunotherapy in alzheimer\u2019s disease. Acta Neuropathol Commun. 2020;8(1):13.","journal-title":"Acta Neuropathol Commun"},{"key":"1775_CR43","unstructured":"Wildsmith K, Horie K, Charil A, Barthelemy N, Verbel D, Reihac-Iaborde A et al. Anti-tau therapeutic antibody, E2814, reduces early and late tau pathology biomarkers in patients with DIAD. In: Clinical Trials on Alzheimer\u2019s Disease Conference. Madrid; 2024."},{"key":"1775_CR44","unstructured":"Eisai Co, Ltd. EISAI presents latest clinical findings suggesting inhibition of tau propagation by anti-MTBR tau, antibody E2814 at the 17th clinical trials on alzheimer\u2019s disease conference (CTAD) [Internet]. 2024 Oct [cited 2025 Feb 2]. Available from: https:\/\/media-us.eisai.com\/2024-10-30-eisai-presents-latest-clinical-findings-suggesting-inhibition-of-tau-propagation-by-anti-mtbr-tau-antibody-e2814-at-the-17th-clinical-trials-on-alzheimers-disease-conference-ctad"},{"issue":"6","key":"1775_CR45","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery CJ, B\u00f6rjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Tau-targeting antisense oligonucleotide MAPTRx in mild alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023;29(6):1437\u201347.","journal-title":"Nat Med"},{"issue":"12","key":"1775_CR46","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","volume":"80","author":"AL Edwards","year":"2023","unstructured":"Edwards AL, Collins JA, Junge C, Kordasiewicz H, Mignon L, Wu S, et al. Exploratory Tau biomarker results from a multiple Ascending-Dose study of BIIB080 in alzheimer disease. JAMA Neurol. 2023;80(12):1344.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1775_CR47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00401-017-1668-z","volume":"133","author":"H Takahashi","year":"2017","unstructured":"Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, et al. Opposing effects of progranulin deficiency on amyloid and Tau pathologies via microglial TYROBP network. Acta Neuropathol. 2017;133(5):785\u2013807.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1775_CR48","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41467-024-45692-3","volume":"15","author":"H Takahashi","year":"2024","unstructured":"Takahashi H, Bhagwagar S, Nies SH, Ye H, Han X, Chiasseu MT, et al. Reduced progranulin increases Tau and \u03b1-synuclein inclusions and alters mouse Tauopathy phenotypes via glucocerebrosidase. Nat Commun. 2024;15(1):1434.","journal-title":"Nat Commun"},{"key":"1775_CR49","unstructured":"Mart\u00e9nyi F, Campbell B, Kinney GG, Lee J, Johnson AD, Swanson C et al. PRX005, A Novel Anti-MTBR Tau Humanized Monoclonal Antibody: Results From the Single Ascending Dose Portion of a First-in-Human Double-Blind, Placebo-Controlled, Phase 1 Clinical Trial. In: Alzheimer\u2019s Association International Conference [Internet]. Amsterdam; 2023 [cited 2024 Dec 31]. Available from: https:\/\/s201.q4cdn.com\/351053094\/files\/doc_presentations\/2023\/07\/16\/P74181_Martenyi_PRX005-SAD-AAIC-2023-Poster_FINAL.pdf"},{"issue":"6","key":"1775_CR50","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.14283\/jpad.2024.163","volume":"11","author":"WR Galpern","year":"2024","unstructured":"Galpern WR, Triana-Baltzer G, Li L, Van Kolen K, Timmers M, Haeverans K, et al. Phase 1 studies of the Anti-Tau monoclonal antibody JNJ-63733657 in healthy participants and participants with alzheimer\u2019s disease. J Prev Alzheimers Dis. 2024;11(6):1592\u2013603.","journal-title":"J Prev Alzheimers Dis"},{"key":"1775_CR51","unstructured":"Johnson & Johnson, Johnson. & Johnson\u2019s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer\u2019s Disease [Internet]. 2025 Jan [cited 2025 Jan 7]. Available from: https:\/\/www.prnewswire.com\/news-releases\/johnson--johnsons-posdinemab-and-tau-active-immunotherapy-receive-us-fda-fast-track-designations-for-the-treatment-of-alzheimers-disease-302345029.html"},{"key":"1775_CR52","unstructured":"Henley D, Bogert J, Saad ZS, Triana-Baltzer G, Wang T, Kolb HC et al. Study Design and Screening Experience from the Phase 2 AU\u03a4ONOMY Trial of Anti-P-Tau Monocloncal Antibody Posdinemab for Early Alzheimer\u2019s Disease. In: 17th Clinical Trials on Alzheimer\u2019s Disease conference [Internet]. Madrid; 2024 [cited 2024 Dec 31]. Available from: https:\/\/www.ctad-alzheimer.com\/files\/files\/PROGRAM_CTAD2024_WEB%20October%2014.pdf"},{"issue":"3","key":"1775_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for alzheimer disease pathology. JAMA Neurol. 2024;81(3):255.","journal-title":"JAMA Neurol"},{"key":"1775_CR54","doi-asserted-by":"crossref","unstructured":"Barton ME, Steen B, Van Van Den HLG, Byrnes W, Purcell FE, Southcott SA, et al. Update on the TOGETHER study: a patient- and investigator\u2010blind, randomized, placebo\u2010controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCB0107, in prodromal\u2010to\u2010mild alzheimer\u2019s disease. Alzheimer\u2019s & Dementia; 2022. 18(S10).","DOI":"10.1002\/alz.068973"},{"key":"1775_CR55","unstructured":"Barton ME. Results from TOGETHER, a Phase II study of bepranemab in prodromal\u2013mild AD. In: 17th Clinical Trials on Alzheimer\u2019s Disease [Internet]. Madrid; 2024 [cited 2025 Feb 4]. Available from: https:\/\/www.ctad-alzheimer.com\/files\/files\/PROGRAM_CTAD2024_WEB%20October%2014.pdf"},{"key":"1775_CR56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.nbd.2017.02.010","volume":"102","author":"KP MacPherson","year":"2017","unstructured":"MacPherson KP, Sompol P, Kannarkat GT, Chang J, Sniffen L, Wildner ME, et al. Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiol Dis. 2017;102:81\u201395.","journal-title":"Neurobiol Dis"},{"key":"1775_CR57","doi-asserted-by":"crossref","unstructured":"MacPherson KP, Eidson LN, Houser MC, Weiss BE, Gollihue JL, Herrick MK et al. Soluble TNF mediates amyloid-independent, diet-induced alterations to immune and neuronal functions in an alzheimer\u2019s disease mouse model. Front Cell Neurosci. 2023;17.","DOI":"10.3389\/fncel.2023.895017"},{"key":"1775_CR58","unstructured":"INmune Bio Inc. INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595\u2122 in Alzheimer\u2019s Disease [Internet]. 2022 May [cited 2025 Feb 5]. Available from: https:\/\/www.inmunebio.com\/index.php\/newsroom\/2022-news\/inmune-bio-inc-to-provide-additional-manufacturing-information-to-fda-as-part-of-ind-application-for-xpro1595-tm-in-alzheimers-disease"},{"key":"1775_CR59","unstructured":"INmune Bio Inc. INmune Bio: FDA Removes Clinical Hold For Alzheimer\u2019s DIsease Program [Internet]. 2024 Jan [cited 2025 Feb 5]. Available from: https:\/\/www.inmunebio.com\/index.php\/newsroom\/2024-news\/inmune-bio-fda-removes-clinical-hold-for-alzheimers-disease-program"},{"key":"1775_CR60","unstructured":"Ferrer Internacional SA. Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP) [Internet]. 2023 Feb [cited 2025 Feb 6]. Available from: https:\/\/ferrer.com\/en\/We-acquire-worldwide-rights-to-ASN90-an-O-GlcNAcase-inhibitor-to-treat-Progressive-Supranuclear-Palsy"},{"key":"1775_CR61","doi-asserted-by":"crossref","unstructured":"Falcicchia C, Tozzi F, Arancio O, Watterson DM, Origlia N. Involvement of p38 MAPK in synaptic function and dysfunction. Int J Mol Sci. 2020;21(16).","DOI":"10.3390\/ijms21165624"},{"key":"1775_CR62","unstructured":"Alam J, Blackburn K, Patrick D, Neflamapimod. Clinical phase 2b-Ready oral small molecule inhibitor of p38\u03b1 to reverse synaptic dysfunction in early alzheimer\u2019s disease. J Prev Alzheimers Dis. 2017;4(4):273\u20138."},{"issue":"1","key":"1775_CR63","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s40478-020-01034-0","volume":"8","author":"T Yang","year":"2020","unstructured":"Yang T, Liu H, Tran KC, Leng A, Massa SM, Longo FM. Small-molecule modulation of the p75 neurotrophin receptor inhibits a wide range of Tau molecular pathologies and their sequelae in P301S Tauopathy mice. Acta Neuropathol Commun. 2020;8(1):156.","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"1775_CR64","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/s41591-024-02977-w","volume":"30","author":"HRC Shanks","year":"2024","unstructured":"Shanks HRC, Chen K, Reiman EM, Blennow K, Cummings JL, Massa SM, et al. p75 neurotrophin receptor modulation in mild to moderate alzheimer disease: a randomized, placebo-controlled phase 2a trial. Nat Med. 2024;30(6):1761\u201370.","journal-title":"Nat Med"},{"issue":"1","key":"1775_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/JAD-151013","volume":"51","author":"M Tong","year":"2016","unstructured":"Tong M, Deochand C, Didsbury J, de la Monte SM. T3D-959: A Multi-Faceted disease remedial drug candidate for the treatment of alzheimer\u2019s disease. J Alzheimer\u2019s Disease. 2016;51(1):123\u201338.","journal-title":"J Alzheimer\u2019s Disease"},{"key":"1775_CR66","doi-asserted-by":"crossref","unstructured":"Stanek J, Chamberlain S, Coutlee C, Strittmatter W, Linebarry C, Swearingen B et al. Topline Results From the Phase 2 PIONEER Trial of Oral T3D-959 For the Treatment of Patients Diagnosed With Mild-To-Moderate Alzheimer\u2019s Disease. In: 16th Clinical Trials on Alzheimer\u2019s Disease conference [Internet]. 2023 [cited 2025 Jan 31]. Available from: https:\/\/www.ctad-alzheimer.com\/files\/files\/CTAD%20ABSTRACT%202023%20oct%2024_compressed.pdf","DOI":"10.1002\/alz.095625"},{"key":"1775_CR67","doi-asserted-by":"crossref","unstructured":"Stanek J, Swearingen B, Strittmatter W, Chamberlain S, Gabriel H, Coutlee C et al. Phase 2 PIONEER Trial of Oral T3D-959 for the Treatment of Patients Diagnosed with Mild-to-Moderate Alzheimer\u2019s Disease: New Results in a Modified Intent-to-Treat Population. In: Alzheimer\u2019s Association International Conference. Philadelphia; 2024.","DOI":"10.1002\/alz.095625"},{"key":"1775_CR68","unstructured":"Transposon Therapeutics Inc. Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy [Internet]. 2024 May [cited 2025 Feb 6]. Available from: https:\/\/www.transposonrx.com\/pdf\/Transposon%20-%20Press%20Release%20-%20Fast%20Track%20Designation%20-%20May%2021,%202024.pdf"},{"key":"1775_CR69","unstructured":"Transposon Therapeutics Inc. Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and\/or Frontotemporal Dementia [Internet]. 2024 Jul [cited 2025 Feb 6]. Available from: https:\/\/www.transposonrx.com\/pdf\/Transposon%20-%20Press%20Release%20-%20Final%20C9%20Results%20-%20July%2024,%202024.pdf"},{"key":"1775_CR70","doi-asserted-by":"crossref","unstructured":"Grill JD, Tam S, Thai G, Vides B, Pierce AL, Green K et al. Phase 2A Proof-of-Concept Double-Blind, randomized, Placebo-Controlled trial of nicotinamide in early alzheimer disease. Neurology. 2025;104(1).","DOI":"10.1212\/WNL.0000000000210152"},{"issue":"s1","key":"1775_CR71","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.3233\/JAD-231126","volume":"101","author":"HH Feldman","year":"2024","unstructured":"Feldman HH, Messer K, Qiu Y, Sabbagh M, Galasko D, Turner RS, et al. Varoglutamstat: inhibiting glutaminyl cyclase as a novel target of therapy in early alzheimer\u2019s disease. J Alzheimers Dis. 2024;101(s1):S79\u201393.","journal-title":"J Alzheimers Dis"},{"key":"1775_CR72","unstructured":"Vivoryon Therapeutics NV, Vivoryon Therapeutics NV. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat\u2019s Potential to Improve Kidney Function [Internet]. 2024 Dec [cited 2025 Feb 5]. Available from: https:\/\/www.globenewswire.com\/news-archive\/2993442\/11666\/en\/Vivoryon-Therapeutics-N-V-Presents-Topline-Phase-2-Data-from-VIVA-MIND-Strongly-Supporting-Varoglutamstat-s-Potential-to-Improve-Kidney-Function.html\/timezone\/Romance%20Standard%20Time?dateformat=dd+MMM+yyyy+HH%3amm"},{"key":"1775_CR73","unstructured":"Vivoryon Therapeutics NV, Vivoryon Therapeutics NV. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer\u2019s Disease [Internet]. 2024 Mar [cited 2025 Feb 5]. Available from: https:\/\/www.globenewswire.com\/news-release\/2024\/03\/04\/2839216\/0\/en\/Vivoryon-Therapeutics-N-V-Provides-Update-on-VIVIAD-Phase-2b-Study-of-Varoglutamstat-in-Early-Alzheimer-s-Disease.html"},{"issue":"8","key":"1775_CR74","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S1470-2045(14)70236-0","volume":"15","author":"G Middleton","year":"2014","unstructured":"Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 2014;15(8):829\u201340.","journal-title":"Lancet Oncol"},{"key":"1775_CR75","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuro.2016.05.022","volume":"55","author":"HH Park","year":"2016","unstructured":"Park HH, Yu HJ, Kim S, Kim G, Choi NY, Lee EH, et al. Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals. Neurotoxicology. 2016;55:131\u201341.","journal-title":"Neurotoxicology"},{"issue":"6","key":"1775_CR76","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.neurobiolaging.2013.12.015","volume":"35","author":"HH Park","year":"2014","unstructured":"Park HH, Lee KY, Kim S, Lee JW, Choi NY, Lee EH, et al. The novel vaccine peptide GV1001 effectively blocks \u03b2-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiol Aging. 2014;35(6):1255\u201374.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1775_CR77","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13195-021-00803-w","volume":"13","author":"SH Koh","year":"2021","unstructured":"Koh SH, Kwon HS, Choi SH, Jeong JH, Na HR, Lee CN, et al. Efficacy and safety of GV1001 in patients with moderate-to-severe alzheimer\u2019s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther. 2021;13(1):66.","journal-title":"Alzheimers Res Ther"},{"key":"1775_CR78","unstructured":"GemVax & KAEL Co. Ltd. GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024 [Internet]. 2024 Oct [cited 2025 Feb 6]. Available from: https:\/\/www.prnewswire.com\/news-releases\/gemvax-announces-topline-results-from-phase-2a-progressive-supranuclear-palsy-clinical-trial-at-neuro2024-302289880.html"},{"key":"1775_CR79","unstructured":"AC Immune SA. AC Immune\u2019s Alzheimer\u2019s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b\/2a Study. 2021 Feb 11 [cited 2025 Feb 6]; Available from: https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-alzheimers-vaccine-generates-potent-anti-ptau"},{"key":"1775_CR80","unstructured":"AC Immune SA, Immune\u2019s AC. ACI-35.030 (now JNJ-2056) Granted FDA Fast Track Designation for Alzheimer\u2019s Disease [Internet]. 2024 Jul [cited 2025 Feb 6]. Available from: https:\/\/ir.acimmune.com\/news-releases\/news-release-details\/ac-immunes-aci-35030-now-jnj-2056-granted-fda-fast-track#:~:text=It%20is%20designed%20to%20test,cognitive%20impairment%20or%20other%20clinical"},{"issue":"26","key":"1775_CR81","doi-asserted-by":"publisher","first-page":"24978","DOI":"10.1074\/jbc.M501565200","volume":"280","author":"MD Mukrasch","year":"2005","unstructured":"Mukrasch MD, Biernat J, von Bergen M, Griesinger C, Mandelkow E, Zweckstetter M. Sites of Tau important for aggregation populate \u03b2-Structure and bind to microtubules and polyanions. J Biol Chem. 2005;280(26):24978\u201386.","journal-title":"J Biol Chem"},{"key":"1775_CR82","doi-asserted-by":"crossref","unstructured":"Song HL, Kim NY, Park J, Kim M, Il, Jeon YN, Lee SJ et al. Monoclonal antibody Y01 prevents Tauopathy progression induced by lysine 280\u2013acetylated Tau in cell and mouse models. J Clin Invest. 2023;133(8).","DOI":"10.1172\/JCI156537"},{"key":"1775_CR83","doi-asserted-by":"crossref","unstructured":"Tai HC, Ma HT, Huang SC, Wu MF, Wu CL, Lai YT et al. The Tau oligomer antibody APNmAb005 detects early-stage pathological Tau enriched at synapses and rescues neuronal loss in long-term treatments. 2022.","DOI":"10.1101\/2022.06.24.497452"},{"key":"1775_CR84","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1096\/fj.202401704R","volume":"38","author":"H Fukumoto","year":"2024","unstructured":"Fukumoto H, Kao T, Tai C, Jang M, Miyamoto M. High-molecular\u2010weight oligomer Tau (<\u2009scp\u2009>\u2009HMWoTau) species are dramatically increased in Braak\u2010stage dependent manner in the frontal lobe of human brains, demonstrated by a novel oligomer tau\u2009<\u2009scp\u2009>\u2009elisa\u2009with a mouse monoclonal antibody (<\u2009scp\u2009>\u2009APNmAb005). FASEB J. 2024;38:22.","journal-title":"FASEB J"},{"key":"1775_CR85","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/alz.076888","volume":"19","author":"C Tai","year":"2023","unstructured":"Tai C, Ma H, Li C, Fang Wu M, Wang S, Wu C, et al. APNmAb005, an anti-tau antibody targeting synaptic Tau oligomers, in phase 1 for treatment of alzheimer\u2019s disease and primary Tauopathies. Alzheimer\u2019s Dement. 2023;19:S21.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"3","key":"1775_CR86","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1021\/jasms.2c00324","volume":"34","author":"AM Jacobsen","year":"2023","unstructured":"Jacobsen AM, van de Merbel NC, Ditlevsen DK, Tvermosegaard K, Schalk F, Lambert W, et al. A quantitative LC-MS\/MS method for distinguishing the Tau protein forms phosphorylated and nonphosphorylated at Serine-396. J Am Soc Mass Spectrom. 2023;34(3):441\u201351.","journal-title":"J Am Soc Mass Spectrom"},{"key":"1775_CR87","doi-asserted-by":"crossref","unstructured":"Rosenqvist N, Asuni AA, Andersson CR, Christensen S, Daechsel JA, Egebjerg J et al. Highly specific and selective anti-pS396\u2010tau antibody C10.2 targets seeding\u2010competent tau. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2018;4(1):521\u201334.","DOI":"10.1016\/j.trci.2018.09.005"},{"issue":"3","key":"1775_CR88","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/acn3.171","volume":"2","author":"T Umeda","year":"2015","unstructured":"Umeda T, Eguchi H, Kunori Y, Matsumoto Y, Taniguchi T, Mori H, et al. Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol. 2015;2(3):241\u201355.","journal-title":"Ann Clin Transl Neurol"},{"issue":"s1","key":"1775_CR89","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.3233\/JAD-231238","volume":"101","author":"EM Sigurdsson","year":"2024","unstructured":"Sigurdsson EM. Tau immunotherapies for alzheimer\u2019s disease and related tauopathies: status of trials and insights from preclinical studies. J Alzheimers Dis. 2024;101(s1):S129\u201340.","journal-title":"J Alzheimers Dis"},{"key":"1775_CR90","unstructured":"Voyager Therapeutics Inc. Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer\u2019s Disease [Internet]. Lexington, MA. 2024 May [cited 2025 Jan 10]. Available from: https:\/\/ir.voyagertherapeutics.com\/news-releases\/news-release-details\/voyager-therapeutics-announces-first-participants-dosed-single"},{"key":"1775_CR91","unstructured":"Voyager Therapeutics. Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer\u2019s Disease [Internet]. Lexington; 2025 Mar [cited 2025 Mar 2]. Available from: https:\/\/ir.voyagertherapeutics.com\/news-releases\/news-release-details\/voyager-reports-positive-topline-data-single-ascending-dose-sad?utm_source=LinkedIn%26utm_medium=organic%26utm_campaign=SAD\/MAD_March2025"},{"key":"1775_CR92","unstructured":"Voyager Therapeutics Inc. Defining Neurogenetic Medicines. In: Wells Fargo 2024 Healthcare Conference [Internet]. 2024 [cited 2025 Feb 10]. Available from: https:\/\/ir.voyagertherapeutics.com\/static-files\/534b5eff-5708-4a79-b493-3b58c071d788"},{"issue":"1","key":"1775_CR93","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpdd.1323","volume":"13","author":"EO Fadiran","year":"2024","unstructured":"Fadiran EO, Hammond E, Tran J, Missling CU, Ette E. Population-Based characterization of the pharmacokinetics and food effect of ANAVEX3\u201071, a novel Sigma\u20101 receptor and allosteric M1 muscarinic receptor agonist in development for treatment of frontotemporal dementia, schizophrenia, and alzheimer disease. Clin Pharmacol Drug Dev. 2024;13(1):21\u201331.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"1775_CR94","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpdd.1303","volume":"12","author":"EO Fadiran","year":"2023","unstructured":"Fadiran EO, Hammond E, Tran J, Xue H, Chen J, Kaufmann WE, et al. Concentration\u2013QTc relationship from a single ascending dose study of ANAVEX3-71, a novel Sigma\u20101 receptor and allosteric M1 muscarinic receptor agonist in development for the treatment of frontotemporal dementia, schizophrenia, and alzheimer\u2019s disease. Clin Pharmacol Drug Dev. 2023;12(9):888\u2013901.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"1775_CR95","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2967\/jnumed.122.265225","volume":"64","author":"BE Cook","year":"2023","unstructured":"Cook BE, Nag S, Arakawa R, Lin EYS, Stratman N, Guckian K, et al. Development of a PET tracer for OGA with improved kinetics in the living brain. J Nucl Med. 2023;64(10):1588\u201393.","journal-title":"J Nucl Med"},{"key":"1775_CR96","unstructured":"Nery FC. Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers. In: AD\/PD. 2024. Lisbon; 2024."},{"key":"1775_CR97","unstructured":"Lee H, Choi SH, Moon JH, Lee MJ, Doh H. Neuroprotective effect of DA-7503, a novel tau aggregation inhibitor, against okadaic acid-induced tauopathy in vitro and in vivo. In: AD\/PD. 2023. Gothenburg; 2023."},{"issue":"1","key":"1775_CR98","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3233\/JAD-190465","volume":"73","author":"EJ Davidowitz","year":"2020","unstructured":"Davidowitz EJ, Krishnamurthy PK, Lopez P, Jimenez H, Adrien L, Davies P, et al. Vivo validation of a small molecule inhibitor of Tau Self-Association in Htau mice. J Alzheimer\u2019s Disease. 2020;73(1):147\u201361.","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"8","key":"1775_CR99","doi-asserted-by":"publisher","first-page":"e0286523","DOI":"10.1371\/journal.pone.0286523","volume":"18","author":"EJ Davidowitz","year":"2023","unstructured":"Davidowitz EJ, Lopez P, Jimenez H, Adrien L, Davies P, Moe JG. Small molecule inhibitor of Tau self-association in a mouse model of Tauopathy: A preventive study in P301L Tau JNPL3 mice. PLoS ONE. 2023;18(8):e0286523.","journal-title":"PLoS ONE"},{"key":"1775_CR100","doi-asserted-by":"crossref","unstructured":"Davidowitz EJ, Lopez P, Patel D, Jimenez H, Wolin A, Eun J et al. Therapeutic treatment with OLX-07010 inhibited Tau aggregation and ameliorated motor deficits in an aged mouse model of tauopathy. J Neurochem. 2025;169(3).","DOI":"10.1111\/jnc.70025"},{"key":"1775_CR101","doi-asserted-by":"crossref","unstructured":"Wu Z, Deng X, Hu Q, Xiao X, Jiang J, Ma X et al. Houttuynia cordata thunb: an ethnopharmacological review. Front Pharmacol. 2021;12.","DOI":"10.3389\/fphar.2021.714694"},{"issue":"9","key":"1775_CR102","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/ph15091079","volume":"15","author":"S Rafiq","year":"2022","unstructured":"Rafiq S, Hao H, Ijaz M, Raza A. Pharmacological effects of Houttuynia cordata thunb (H. cordata): A comprehensive review. Pharmaceuticals. 2022;15(9):1079.","journal-title":"Pharmaceuticals"},{"key":"1775_CR103","volume-title":"Methods of treatment or prevention of acute brain or nerve injuries","author":"M Maccecchini","year":"2017","unstructured":"Maccecchini M. Methods of treatment or prevention of acute brain or nerve injuries. Volume WO2017030968A1. United States: World Intellectual Property Organization; 2017."},{"key":"1775_CR104","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1002\/alz.082687","volume":"19","author":"C Tourino","year":"2023","unstructured":"Tourino C, Trumble A, Louie L, Barbour RM, Kinney GG, Campbell B, et al. Immunological response to dual A\u03b2\/Tau vaccine PRX123 surrogate and effects on brain amyloid plaques in rapidly depositing Transgenic animal model. Alzheimer\u2019s Dement. 2023;19:S24.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1775_CR105","doi-asserted-by":"crossref","unstructured":"Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R et al. Randomized phase II study of the safety and efficacy of semorinemab in participants with Mild-to-Moderate alzheimer disease: Lauriet. Neurology. 2023;101(14).","DOI":"10.1212\/WNL.0000000000207861"},{"issue":"12","key":"1775_CR106","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1002\/alz.14346","volume":"20","author":"SP Schauer","year":"2024","unstructured":"Schauer SP, Toth B, Lee J, Honigberg LA, Ramakrishnan V, Jiang J, et al. Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of alzheimer\u2019s disease pathophysiology. Alzheimer\u2019s Dement. 2024;20(12):8855\u201366.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1775_CR107","doi-asserted-by":"crossref","unstructured":"Princen K, Van Dooren T, van Gorsel M, Louros N, Yang X, Dumbacher M et al. Pharmacological modulation of septins restores calcium homeostasis and is neuroprotective in models of Alzheimer\u2019s disease. Science (1979). 2024;384(6699).","DOI":"10.1126\/science.add6260"},{"key":"1775_CR108","unstructured":"reMYND. reMYND announces positive Phase 2a clinical trial results for treatment of mild-to-moderate Alzheimer\u2019s disease [Internet]. 2024 Oct [cited 2025 Feb 5]. Available from: https:\/\/www.remynd.com\/about-us\/news\/remynd-announces-positive-phase-2a-clinical-trial-results-treatment-mild-moderate"},{"key":"1775_CR109","volume-title":"Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of alzheimer\u2019s disease","author":"W Kielbasa","year":"2024","unstructured":"Kielbasa W, Goldsmith P, Donnelly KB, Nuthall HN, Shcherbinin S, Fleisher AS, et al. Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of alzheimer\u2019s disease. Volume 10. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions; 2024. 4."},{"key":"1775_CR110","unstructured":"Fleisher AS, Munsie L, Mancini M, Cheng EYJ, Shcherbinin S, Nakamura T et al. PROSPECT-ALZ: Results of the phase 2 study of ceperognastat, an orally available O-linked N-acetyl glucosaminidase inhibitor for the treatment of early symptomatic Alzheimer\u2019s disease. In: Clinical Trials on Alzheimer\u2019s Disease conference [Internet]. 2024 [cited 2025 Feb 19]. Available from: https:\/\/assets.ctfassets.net\/mpejy6umgthp\/jLMZSYBfH43BzC2NJDejW\/cbaa5093c20034b60118fb565733c804\/DV-022295_OC10_MTAE_Fleisher_V2-2024_1029-MDD.pdf"},{"key":"1775_CR111","unstructured":"Asceneuron SA. Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases [Internet]. 2024 Jul [cited 2025 Feb 6]. Available from: https:\/\/asceneuron.com\/asceneuron-secures-100-million-series-c-financing\/"},{"issue":"2","key":"1775_CR112","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1021\/acschemneuro.4c00319","volume":"16","author":"H Wongso","year":"2025","unstructured":"Wongso H, Harada R, Furumoto S. Current progress and future directions in Non-Alzheimer\u2019s disease Tau PET tracers. ACS Chem Neurosci. 2025;16(2):111\u201327.","journal-title":"ACS Chem Neurosci"},{"key":"1775_CR113","unstructured":"FDA: Center for Drug Evaluation and Research. Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs [Internet]. 2012 [cited 2025 Mar 4]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/investigational-new-drug-applications-positron-emission-tomography-pet-drugs"},{"key":"1775_CR114","doi-asserted-by":"crossref","unstructured":"Burnham SC, Iaccarino L, Pontecorvo MJ, Fleisher AS, Lu M, Collins EC et al. A review of the flortaucipir literature for positron emission tomography imaging of Tau neurofibrillary tangles. Brain Commun. 2023;6(1).","DOI":"10.1093\/braincomms\/fcad305"},{"key":"1775_CR115","doi-asserted-by":"crossref","unstructured":"Vermeiren MR, Calandri IL, van der Flier WM, van de Giessen E, Ossenkoppele R. Survey among experts on the future role of tau-PET in clinical practice and trials. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2024;16(4).","DOI":"10.1002\/dad2.70033"},{"issue":"2","key":"1775_CR116","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1039\/D4MD00576G","volume":"16","author":"S Mekala","year":"2025","unstructured":"Mekala S, Wu Y, Li YM. Strategies of positron emission tomography (PET) tracer development for imaging of Tau and \u03b1-synuclein in neurodegenerative disorders. RSC Med Chem. 2025;16(2):605\u201339.","journal-title":"RSC Med Chem"},{"issue":"6","key":"1775_CR117","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","volume":"9","author":"C Xia","year":"2013","unstructured":"Xia C, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [18F]T807, a novel Tau positron emission tomography imaging agent for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2013;9(6):666\u201376.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1775_CR118","unstructured":"Aprinoia Therapeutics. APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 for the Diagnosis of Progressive Supranuclear Palsy [Internet]. Cambridge. 2024 May [cited 2025 Mar 4]. Available from: https:\/\/aprinoia.com\/aprinoia-therapeutics-announces-fast-track-designation-granted-by-u-s-fda-to-apn-1607-florzolotau-for-the-diagnosis-of-progressive-supranuclear-palsy\/"},{"issue":"10","key":"1775_CR119","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","volume":"46","author":"S Sanabria Boh\u00f3rquez","year":"2019","unstructured":"Sanabria Boh\u00f3rquez S, Marik J, Ogasawara A, Tinianow JN, Gill HS, Barret O, et al. [18F]GTP1 (Genentech Tau probe 1), a radioligand for detecting neurofibrillary tangle Tau pathology in alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2019;46(10):2077\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1775_CR120","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2967\/jnumed.124.268623","volume":"66","author":"E Olafson","year":"2025","unstructured":"Olafson E, Tonietto M, Klein G, Teng E, Stephens AW, Russell DS, et al. In vivo Head-to-Head comparison of [18F]GTP1 with [18F]MK-6240 and [18F]PI-2620 in alzheimer disease. J Nucl Med. 2025;66(2):277\u201385.","journal-title":"J Nucl Med"},{"issue":"4","key":"1775_CR121","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2967\/jnumed.117.196741","volume":"59","author":"M Honer","year":"2018","unstructured":"Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, et al. Preclinical evaluation of 18F-RO6958948, 11\u00a0C-RO6931643, and 11\u00a0C-RO6924963 as novel PET radiotracers for imaging Tau aggregates in alzheimer disease. J Nucl Med. 2018;59(4):675\u201381.","journal-title":"J Nucl Med"},{"issue":"17","key":"1775_CR122","doi-asserted-by":"publisher","first-page":"7350","DOI":"10.1021\/acs.jmedchem.7b00632","volume":"60","author":"LC Gobbi","year":"2017","unstructured":"Gobbi LC, Knust H, K\u00f6rner M, Honer M, Czech C, Belli S, et al. Identification of three novel radiotracers for imaging aggregated Tau in alzheimer\u2019s disease with positron emission tomography. J Med Chem. 2017;60(17):7350\u201370.","journal-title":"J Med Chem"},{"issue":"5","key":"1775_CR123","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-022-06065-4","volume":"50","author":"AF Santillo","year":"2023","unstructured":"Santillo AF, Leuzy A, Honer M, Landqvist Wald\u00f6 M, Tideman P, Harper L, et al. [18F]RO948 Tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes. Eur J Nucl Med Mol Imaging. 2023;50(5):1371\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1775_CR124","unstructured":"Lantheus. Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer\u2019s Disease [Internet]. Bedford; 2023 Feb [cited 2025 Mar 4]. Available from: https:\/\/lantheusholdings.gcs-web.com\/news-releases\/news-release-details\/lantheus-announces-acquisition-cerveau-technologies-inc"},{"issue":"10","key":"1775_CR125","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","volume":"57","author":"ED Hostetler","year":"2016","unstructured":"Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57(10):1599\u2013606.","journal-title":"J Nucl Med"},{"issue":"1","key":"1775_CR126","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13195-018-0402-y","volume":"10","author":"TA Pascoal","year":"2018","unstructured":"Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimers Res Ther. 2018;10(1):74.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1775_CR127","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41380-022-01875-2","volume":"28","author":"ML Malarte","year":"2023","unstructured":"Malarte ML, Gillberg PG, Kumar A, Bogdanovic N, Lemoine L, Nordberg A. Discriminative binding of Tau PET tracers PI2620, MK6240 and RO948 in alzheimer\u2019s disease, corticobasal degeneration and progressive supranuclear palsy brains. Mol Psychiatry. 2023;28(3):1272\u201383.","journal-title":"Mol Psychiatry"},{"issue":"18","key":"1775_CR128","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1021\/acschemneuro.3c00437","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, Kumar A, L\u00e5ngstr\u00f6m B, Nordberg A, \u00c5gren H. Insight into the binding of First- and Second-Generation PET tracers to 4R and 3R\/4R Tau protofibrils. ACS Chem Neurosci. 2023;14(18):3528\u201339.","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"1775_CR129","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2967\/jnumed.119.236224","volume":"61","author":"A Mueller","year":"2020","unstructured":"Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C, et al. Tau PET imaging with 18F-PI-2620 in patients with alzheimer disease and healthy controls: A First-in-Humans study. J Nucl Med. 2020;61(6):911\u20139.","journal-title":"J Nucl Med"},{"key":"1775_CR130","unstructured":"Life Molecular Imaging. Life Molecular Imaging Receives FDA Fast Track Designation for [18F]PI-2620 in Tau PET Imaging Across Three Neurodegenerative Conditions [Internet]. Boston; 2024 Aug [cited 2025 Mar 4]. Available from: https:\/\/life-mi.com\/life-molecular-imaging-receives-fda-fast-track-designation-for-18fpi-2620-in-tau-pet-imaging-across-three-neurodegenerative-conditions\/"},{"issue":"4","key":"1775_CR131","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1021\/acschemneuro.0c00801","volume":"12","author":"A Lindberg","year":"2021","unstructured":"Lindberg A, Knight AC, Sohn D, Rakos L, Tong J, Radelet A, et al. Radiosynthesis, in vitro and in vivo evaluation of [18F]CBD-2115 as a First-in-Class Radiotracer for imaging 4R-Tauopathies. ACS Chem Neurosci. 2021;12(4):596\u2013602.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1775_CR132","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1038\/s41467-024-49258-1","volume":"15","author":"A Lindberg","year":"2024","unstructured":"Lindberg A, Murrell E, Tong J, Mason NS, Sohn D, Sandell J, et al. Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer\u2019s disease tauopathies. Nat Commun. 2024;15(1):5109.","journal-title":"Nat Commun"},{"key":"1775_CR133","unstructured":"Centre For Addiction and Mental Health. Health Canada Clinical Trials Database.2024 [cited 2025 Mar 4]. Imaging tau with [18F]OXD-2314 in neurodegenerative disorders.Available from: https:\/\/health-products.canada.ca\/ctdb-bdec\/brands?medicalConditionName=%26protocolTitle=%26drugName=OXD%26sponsorName=%26studyPopulationId=%26statusId=%26nolDateFrom=%26nolDateTo=%26startDateFrom=%26startDateTo=%26endDateFrom=%26endDateTo=%26protocolNo=%26submissionNo=%26submit=Search"},{"key":"1775_CR134","doi-asserted-by":"crossref","unstructured":"Chen L, Jiang H, Licinio J, Wu H. Brain O-GlcNAcylation: bridging physiological functions, disease mechanisms, and therapeutic applications. Mol Psychiatry. 2025.","DOI":"10.1038\/s41380-025-02943-z"},{"issue":"1","key":"1775_CR135","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-025-00465-w","volume":"14","author":"BH Kim","year":"2025","unstructured":"Kim BH, Kim S, Nam Y, Park YH, Shin SM, Moon M. Second-generation anti-amyloid monoclonal antibodies for alzheimer\u2019s disease: current landscape and future perspectives. Transl Neurodegener. 2025;14(1):6.","journal-title":"Transl Neurodegener"},{"issue":"12","key":"1775_CR136","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","volume":"140","author":"A Bejanin","year":"2017","unstructured":"Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, et al. Tau pathology and neurodegeneration contribute to cognitive impairment in alzheimer\u2019s disease. Brain. 2017;140(12):3286\u2013300.","journal-title":"Brain"},{"issue":"7","key":"1775_CR137","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM. Tau-targeting therapies for alzheimer disease. Nat Rev Neurol. 2018;14(7):399\u2013415.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"1775_CR138","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, et al. Head-to\u2010head comparison of leading blood tests for alzheimer\u2019s disease pathology. Alzheimer\u2019s Dement. 2024;20(11):8074\u201396.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"6","key":"1775_CR139","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1002\/alz.12906","volume":"19","author":"D Aguillon","year":"2023","unstructured":"Aguillon D, Langella S, Chen Y, Sanchez JS, Su Y, Vila-Castelar C, et al. Plasma p\u2010tau217 predicts in vivo brain pathology and cognition in autosomal dominant alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2023;19(6):2585\u201394.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"2","key":"1775_CR140","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/brain\/awae346","volume":"148","author":"N Warmenhoven","year":"2025","unstructured":"Warmenhoven N, Salvad\u00f3 G, Janelidze S, Mattsson-Carlgren N, Bali D, Ordu\u00f1a Dolado A, et al. A comprehensive head-to-head comparison of key plasma phosphorylated Tau 217 biomarker tests. Brain. 2025;148(2):416\u201331.","journal-title":"Brain"},{"issue":"2","key":"1775_CR141","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41591-024-03400-0","volume":"31","author":"T Islam","year":"2025","unstructured":"Islam T, Hill E, Abrahamson EE, Servaes S, Smirnov DS, Zeng X, et al. Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble Tau assemblies in alzheimer\u2019s disease. Nat Med. 2025;31(2):574\u201388.","journal-title":"Nat Med"},{"issue":"6","key":"1775_CR142","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/s41591-024-02937-4","volume":"30","author":"M Chatterjee","year":"2024","unstructured":"Chatterjee M, \u00d6zdemir S, Fritz C, M\u00f6bius W, Kleineidam L, Mandelkow E, et al. Plasma extracellular vesicle Tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nat Med. 2024;30(6):1771\u201383.","journal-title":"Nat Med"},{"issue":"1","key":"1775_CR143","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/v16010072","volume":"16","author":"D Guha","year":"2023","unstructured":"Guha D, Misra V, Chettimada S, Yin J, Gabuzda D. CSF extracellular vesicle A\u03b242 and Tau\/A\u03b242 ratio are associated with cognitive impairment in older people with HIV. Viruses. 2023;16(1):72.","journal-title":"Viruses"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01775-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01775-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:02:42Z","timestamp":1748995362000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01775-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1775"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01775-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have consented for this review paper to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}